clinical trial Archives - Insight Presented by Prime Creative Media Thu, 03 Jun 2021 22:04:56 +0000 en-US hourly 1 https://www.insightnews.com.au/wp-content/uploads/2024/02/cropped-Insight-favicon-32x32.png clinical trial Archives - Insight 32 32 OAW 2021: The role of an orthoptist in clinical trials https://www.insightnews.com.au/oaw-2021-the-role-of-an-orthoptist-in-clinical-trials/ Mon, 31 May 2021 00:26:46 +0000 http://www.insightnews.com.au/?p=20558
Imaging forms part of an orthoptist's tasks in clinical trials.

The World Health Organisation defines a clinical trial as “a type of research that studies new tests and treatments and evaluates their effects on human health outcomes”. Clinical trials areRead More

The post OAW 2021: The role of an orthoptist in clinical trials appeared first on Insight.

]]>
Imaging forms part of an orthoptist's tasks in clinical trials.
The World Health Organisation defines a clinical trial as “a type of research that studies new tests and treatments and evaluates their effects on human health outcomes”. Clinical trials are
Read More

The post OAW 2021: The role of an orthoptist in clinical trials appeared first on Insight.

]]> Gene therapy trial for dry AMD under way in Australia https://www.insightnews.com.au/gene-therapy-trial-for-dry-amd-under-way-in-australia/ Mon, 03 May 2021 04:28:03 +0000 http://www.insightnews.com.au/?p=20111
Melbourne ophthalmologist Dr Tom Edwards (centre), with the team that helped perform the procedure.

The post Gene therapy trial for dry AMD under way in Australia appeared first on Insight.

]]>
Melbourne ophthalmologist Dr Tom Edwards (centre), with the team that helped perform the procedure.
Australia’s first clinical trials of an investigational gene therapy for dry age-related macular degeneration (AMD) has commenced at the Centre for Eye Research Australia (CERA). CERA’s principal investigator
Read More

The post Gene therapy trial for dry AMD under way in Australia appeared first on Insight.

]]> Opthea treats first patient in Phase 3 nAMD trial https://www.insightnews.com.au/opthea-treats-first-patient-in-phase-3-namd-trial/ Mon, 22 Mar 2021 00:11:07 +0000 http://www.insightnews.com.au/?p=19544
Both trials are aiming to each enrol 990 treatment-naïve patients.

The post Opthea treats first patient in Phase 3 nAMD trial appeared first on Insight.

]]>
Both trials are aiming to each enrol 990 treatment-naïve patients.
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular degeneration (nAMD) has been treated in the US. ASX-listed biopharmaceutical
Read More

The post Opthea treats first patient in Phase 3 nAMD trial appeared first on Insight.

]]> Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange https://www.insightnews.com.au/tax-credit-strengthens-optheas-balance-sheet-follows-au175m-ipo-on-us-exchange/ Tue, 17 Nov 2020 21:26:01 +0000 http://www.insightnews.com.au/?p=17802
The ATO's R&D Tax Incentive enables companies to receive 43.5% of eligible research and development expenditure.

The post Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange appeared first on Insight.

]]>
The ATO's R&D Tax Incentive enables companies to receive 43.5% of eligible research and development expenditure.
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ahead of pivotal Phase 3 trials of its lead drug
Read More

The post Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange appeared first on Insight.

]]> Australian glaucoma trial set to expand after vitamin B3 success https://www.insightnews.com.au/australian-glaucoma-trial-set-to-expand-after-vitamin-b3-success/ Thu, 30 Jul 2020 21:39:43 +0000 http://www.insightnews.com.au/?p=15903
Dr Flora Hui, research fellow at the Centre for Eye Research Australia.

The post Australian glaucoma trial set to expand after vitamin B3 success appeared first on Insight.

]]>
Dr Flora Hui, research fellow at the Centre for Eye Research Australia.
Daily doses of vitamin B3 can lead to significant improvements in glaucoma patients who are also receiving regular treatments to lower eye pressure, new results of a world-first study have revealed. The
Read More

The post Australian glaucoma trial set to expand after vitamin B3 success appeared first on Insight.

]]> Opthea becomes ASX top 300 company https://www.insightnews.com.au/opthea-becomes-asx-top-300-company/ Mon, 29 Jun 2020 21:21:05 +0000 http://www.insightnews.com.au/?p=15361
Opthea's share price has soared more than 250% during the past year.

The post Opthea becomes ASX top 300 company appeared first on Insight.

]]>
Opthea's share price has soared more than 250% during the past year.
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met primary end points in the latest clinical trial for diabetic macular edema
Read More

The post Opthea becomes ASX top 300 company appeared first on Insight.

]]> Novartis secures approval for AMD drug in Australia https://www.insightnews.com.au/novartis-secures-approval-for-amd-drug-in-australia/ Tue, 28 Jan 2020 22:38:52 +0000 http://www.insightnews.com.au/?p=13341
Novartis states there is no validated new or changed safety signal for Beovu.

The post Novartis secures approval for AMD drug in Australia appeared first on Insight.

]]>
Novartis states there is no validated new or changed safety signal for Beovu.
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence
Read More

The post Novartis secures approval for AMD drug in Australia appeared first on Insight.

]]>